BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 29506843)

  • 1. Pathologic response following treatment for locally advanced rectal cancer: Does location matter?
    Ward WH; Sigurdson ER; Esposito AC; Ruth KJ; Manstein SM; Sorenson EC; Wernick BD; Farma JM
    J Surg Res; 2018 Apr; 224():215-221. PubMed ID: 29506843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive Significance of Mucinous Histology on Pathologic Complete Response Rate Following Capecitabine-Based Neoadjuvant Chemoradiation in Rectal Cancer: a Comparative Study.
    Hosseini S; Nguyen N; Mohammadianpanah M; Mirzaei S; Bananzadeh AM
    J Gastrointest Cancer; 2019 Dec; 50(4):716-722. PubMed ID: 29984382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival.
    Kim NK; Baik SH; Seong JS; Kim H; Roh JK; Lee KY; Sohn SK; Cho CH
    Ann Surg; 2006 Dec; 244(6):1024-30. PubMed ID: 17122629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CEA - a predictor for pathologic complete response after neoadjuvant therapy for rectal cancer.
    Wallin U; Rothenberger D; Lowry A; Luepker R; Mellgren A
    Dis Colon Rectum; 2013 Jul; 56(7):859-68. PubMed ID: 23739192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-mount pathologic analysis of rectal cancer following neoadjuvant therapy: implications of margin status on long-term oncologic outcome.
    Mezhir JJ; Shia J; Riedel E; Temple LK; Nash GM; Weiser MR; Paty PB; Wong WD; Guillem JG
    Ann Surg; 2012 Aug; 256(2):274-9. PubMed ID: 22791103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distance to the anal verge is associated with pathologic complete response to neoadjuvant therapy in locally advanced rectal cancer.
    Patel SV; Roxburgh CS; Vakiani E; Shia J; Smith JJ; Temple LK; Paty P; Garcia-Aguilar J; Nash G; Guillem J; Wu A; Reyngold M; Weiser MR
    J Surg Oncol; 2016 Oct; 114(5):637-641. PubMed ID: 27641934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is final TNM staging a predictor for survival in locally advanced rectal cancer after preoperative chemoradiation therapy?
    Kuo LJ; Liu MC; Jian JJ; Horng CF; Cheng TI; Chen CM; Fang WT; Chung YL
    Ann Surg Oncol; 2007 Oct; 14(10):2766-72. PubMed ID: 17551794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
    Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307
    [No Abstract]   [Full Text] [Related]  

  • 9. Pretreatment Tumor Thickness as a Predictor of Pathologic Complete Response to Neoadjuvant Chemoradiation Therapy for Stage II/III Rectal Adenocarcinoma.
    Xu B; Chen Y; Guo Y; Zhou D; Yue Z; Duan Q; Yang Y; Guan G; Chi P; Lin C
    Am J Clin Oncol; 2018 Jun; 41(6):601-606. PubMed ID: 27672742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
    Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
    [No Abstract]   [Full Text] [Related]  

  • 11. Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome.
    Pucciarelli S; Toppan P; Friso ML; Russo V; Pasetto L; Urso E; Marino F; Ambrosi A; Lise M
    Dis Colon Rectum; 2004 Nov; 47(11):1798-807. PubMed ID: 15622571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathologic Complete Response in Rectal Cancer: Can We Detect It? Lessons Learned From a Proposed Randomized Trial of Watch-and-Wait Treatment of Rectal Cancer.
    Nahas SC; Rizkallah Nahas CS; Sparapan Marques CF; Ribeiro U; Cotti GC; Imperiale AR; Capareli FC; Chih Chen AT; Hoff PM; Cecconello I
    Dis Colon Rectum; 2016 Apr; 59(4):255-63. PubMed ID: 26953983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
    Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
    BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
    Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
    [No Abstract]   [Full Text] [Related]  

  • 15. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.
    Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J;
    BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation.
    Quah HM; Chou JF; Gonen M; Shia J; Schrag D; Saltz LB; Goodman KA; Minsky BD; Wong WD; Weiser MR
    Cancer; 2008 Jul; 113(1):57-64. PubMed ID: 18442099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective pathologic analysis using whole-mount sections of rectal cancer following preoperative combined modality therapy: implications for sphincter preservation.
    Guillem JG; Chessin DB; Shia J; Suriawinata A; Riedel E; Moore HG; Minsky BD; Wong WD
    Ann Surg; 2007 Jan; 245(1):88-93. PubMed ID: 17197970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pathologic complete response of rectal cancer to preoperative combined-modality therapy results in improved oncological outcome compared with those who achieve no downstaging on the basis of preoperative endorectal ultrasonography.
    Stipa F; Chessin DB; Shia J; Paty PB; Weiser M; Temple LK; Minsky BD; Wong WD; Guillem JG
    Ann Surg Oncol; 2006 Aug; 13(8):1047-53. PubMed ID: 16865595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet and Neutrophil Counts as Predictive Markers of Neoadjuvant Therapy Efficacy in Rectal Cancer.
    Policicchio A; Mercier J; Digklia A; Voutsadakis IA
    J Gastrointest Cancer; 2019 Dec; 50(4):894-900. PubMed ID: 30353366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implications of acellular mucin pools in resected rectal cancer with pathological complete response to neoadjuvant chemoradiation.
    de Campos-Lobato LF; Dietz DW; Stocchi L; Vogel JD; Lavery IC; Goldblum JR; Skacel M; Pelley RJ; Kalady MF
    Colorectal Dis; 2012 Jan; 14(1):62-7. PubMed ID: 21176057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.